CD19 and lymphoma: As shown in Fig. 5b, c, CAR.CD19-T cells in the presence of emapalumab exerted a significant lymphoma control (Fig. 5b, mice from #13 to #16; Fig. 5c, d, bioluminescence average value at day 28 = 5.87E + 05 ± 8.17E + 04), which did not differ from that of mice not exposed to emapalumab (Fig. 5b, mice from #9 to #12; Fig. 5c, bioluminescence average value at day 28 = 6.18E + 05 ± 9.59E + 04; p = 0.58).